



## **REGENXBIO to Host Conference Call on May 9 to Discuss First Quarter 2017 Financial Results and Recent Operational Highlights**

May 2, 2017 8:06 PM EDT

ROCKVILLE, Md., May 02, 2017 (GLOBE NEWSWIRE) -- REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV<sup>®</sup> Technology Platform, today announced that it will host a conference call on Tuesday, May 9, 2017 at 4:30 p.m. ET to discuss its financial results for the quarter ended March 31, 2017 and recent operational highlights.

To access the live call by phone, dial (855) 422-8964 (domestic) or (210) 229-8819 (international), and enter the passcode 13743533. To access a live or recorded webcast of the call, please visit the "Investors" section of the REGENXBIO website at [www.regenxbio.com](http://www.regenxbio.com). The recorded webcast will be available for approximately 30 days following the call.

### **About REGENXBIO Inc.**

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO's NAV<sup>®</sup> Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Platform Licensees are applying the NAV Technology Platform in the development of a broad pipeline of product candidates in multiple therapeutic areas.

CONTACT: [

Investors [

Heather Savelle, 646-395-3734

[heather@argotpartners.com](mailto:heather@argotpartners.com)

Media [

Adam Pawluk, 202-591-4063

[apawluk@jpa.com](mailto:apawluk@jpa.com)



REGENXBIO Inc.